عرض بسيط للتسجيلة

المؤلفAbdel-Naser, Elzouki
المؤلفZahid, Muhammad
المؤلفAkbar, Raza A.
المؤلفAlfitori, Gamal B.
المؤلفCherichi Purayil, Saleema
المؤلفImanullah, Rizwan
المؤلفDanjuma, Mohammed I.
تاريخ الإتاحة2024-02-14T11:15:11Z
تاريخ النشر2020-09-23
اسم المنشورArab Journal of Gastroenterology
المعرّفhttp://dx.doi.org/10.1016/j.ajg.2020.09.008
الاقتباسElzouki, A. N., Zahid, M., Akbar, R. A., Alfitori, G. B., Purayil, S. C., Imanullah, R., & Danjuma, M. I. (2020). Polypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: results from a national quality improvement audit. Arab Journal of Gastroenterology, 21(4), 216-218.
الرقم المعياري الدولي للكتاب1687-1979
معرّف المصادر الموحدhttps://www.sciencedirect.com/science/article/pii/S1687197920301167
معرّف المصادر الموحدhttp://hdl.handle.net/10576/51844
الملخصBackground and Study AimsAuditing of polypharmacy is particularly essential in patients with cirrhosis because of the crucial role of liver in drug metabolism. The aim of this study was to audit the drug prescribed in this group of patients and analyzed the quantity and severity of potential drug-drug interaction. Patients and MethodsIn this cross-sectional study we analyzed the last prescription as recorded in the Electronic Medical Record at the time of discharge for cirrhotic patients who were hospitalized during 24-months study period. Data were also collected for age, gender, and diagnoses. The drugs were analyzed for cross interactions using the Lexicomp-online e-formulary. The drug interactions are classified as: class A: no known interaction, class B: no action needed, Class C: monitor therapy, class D: consider therapy modification, and Class X: the drug should be avoided. ResultsA total of 333 patients with cirrhosis were audited, whereas complete and relevant data were available for 181 patients (134 males, 74%) with a mean age ± SD 59.7 ± 10.1. Out of these, 168 (92.8%) patients were using at least one medicine and the total number of medications used was 808 drugs. The observed average of utilization was 7.8 ± 3.1 drugs (range = 1–17) and 102 (56.3%) patients used polypharmacy. A total of 198 (24.5%) consumed drugs were related to cirrhosis and its complications. Six (3.3%), 30 (16.6%) and 65 (35.9%) patients had Class-X, Class D, and Class C, respectively. Utilization of polypharmacy was statistical significant in patients with class X (83.3%, p = 0.03), class D (16.6%, p = 0.01), and class C (35.9%, p = 0.02). ConclusionThe findings highlight the importance of auditing for polypharmacy to recognize and prevent potential drug-related problems in patients with cirrhosis. Implementation of strategies to optimize medication use in patients with cirrhosis should be considered necessary as it can have a bearing on length of stay and morbidity.
اللغةen
الناشرElsevier
الموضوعPolypharmacy
Cirrhosis
Advanced liver disease
Drug-drug interaction
العنوانPolypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: Results from a national quality improvement audit
النوعArticle
الصفحات216-218
رقم العدد4
رقم المجلد21
ESSN2090-2387
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة